Extended Impact Assessment of a Draft EC Regulation on Medicinal Products for Paediatric Use
Full Document
Full Document
| Format | File Size | Notes |
|---|---|---|
| PDF file | 0.9 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
Summary Only
| Format | File Size | Notes |
|---|---|---|
| PDF file | 0.2 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
There is a serious lack of testing of medicinal products in the paediatric population. The European Commission has attempted to provide a structural solution by drafting a regulation. This report describes the economic, social, sustainable, and environmental impacts of the regulation. The assessment indicates that the proposed regulation will achieve its objectives, although the effects will vary.
Research conducted by
The research described in this report was conducted by RAND Europe for the European Commission.
This report is part of the RAND Corporation Monograph series. RAND monographs present major research findings that address the challenges facing the public and private sectors. All RAND monographs undergo rigorous peer review to ensure high standards for research quality and objectivity.
Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.